Treating these cells with AURKA-GapmeR or Aur-I resulted in decreased AURKA mRNA expression and reduced cell viability in both prostate cancer (Supplementary Figures 8A–C) and pancreatic cancer cells (Supplementary Figures 8D–F). Here, AURKA is linked to prostate cancer.